Harrow, Inc. (HROW) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Harrow, Inc. on October 6, 2025. The report addresses a significant leadership transition within ImprimisRx, LLC, a wholly owned subsidiary of the Company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel changes rather than financial performance.
Material Changes
- Executive Departure: On October 6, 2025, John Saharek ceased serving as President and Chief Executive Officer of ImprimisRx, LLC and certain affiliated entities.
- Role Transition: Mr. Saharek has transitioned to a non-officer leadership role at Harrow, Inc. and will no longer be involved in the operations of ImprimisRx.
- Compensation: No new compensatory arrangements were entered into with Mr. Saharek in connection with this transition.
Guidance, Outlook, and Risks
The filing includes a Regulation FD disclosure referencing a press release (Exhibit 99.1) regarding the leadership changes. The document does not contain updated financial guidance, management commentary on future outlook, or specific risk factors beyond the operational shift at the subsidiary level.
Investor Verification Checklist
- Verify the specific details of Mr. Saharek's new non-officer leadership role and responsibilities.
- Confirm the identity of the successor appointed to lead ImprimisRx operations.
- Review the full text of the press release (Exhibit 99.1) for additional context on the strategic rationale for the change.
- Monitor subsequent filings for any impact on ImprimisRx's operational performance or integration with Harrow's broader strategy.